In the experimental group, zinc sulfate was given intramuscularly each day, beginning 2 days before operation.
This study is the largest ever reported to date to evaluate zinc sulfate in the treatment or prevention of taste alteration for patients receiving radiation therapy for head and neck cancer.
Under these conditions, the iron-removal rate of zinc sulfate leaching solution reaches better effect.
The results showed that the relative bioavailability of zinc L lysinate tablets was markedly superior to zinc sulfate tablets, also higher than zinc gluconate tablets.